Breaking Update: Here’s a clear explanation of the latest developments related to Breaking News:Expanding HPV Vaccine Access in India– What Just Happened and why it matters right now.
The launch of a nationwide human papillomavirus (HPV) vaccination programme for adolescent girls marks a notable step for women’s health. Cervical cancer is the second-most prevalent form of cancer among Indian women, and with HPV being the leading cause, vaccination is crucial. As vaccine hesitancy fuelled by misinformation is on the rise and the politicisation of health continues, India’s sustained steps to safeguard women’s health are a welcome development.
Human papillomavirus (HPV) refers to a group of around 200 related viruses that are sexually transmitted. Although most HPV infections subside on their own, typically without any symptoms, some persistent infections can result in cancer. Progression of an HPV infection into cancer can take up to 15–20 years, while symptoms may not appear during the initial phase when cancer cells begin to develop. There are currently no therapeutic measures to prevent HPV infection, but treatments exist for cervical cancer, with management being most effective when diagnosed early. Cervical cancer is the only HPV-caused cancer for which screening tests are available to detect onset. Accordingly, vaccination against HPV infection is the most effective way to prevent the development of HPV-related cancers, including cervical cancer.
A single dose of MSD’s vaccine, Gardasil®, is prescribed to prevent HPV infection and the development of cervical cancer. This move supports a policy highlight of the interim Union Budget (2024–25), which mentioned steps to introduce cervical cancer vaccination drives.
Integrating HPV Vaccination into Public Health Strategy
The World Health Organization (WHO) recommends that the HPV vaccine be administered to girls aged 9–14 years, with either a single-dose or a two-dose regimen. In the current vaccination drive, the Ministry of Health and Family Welfare (MoHFW) will provide free HPV vaccines to adolescent girls aged 14 years across the country to ensure equitable access. Vaccination is voluntary and requires parental consent. A single dose of MSD’s vaccine, Gardasil®, is prescribed to prevent HPV infection and the development of cervical cancer. This move supports a policy highlight of the interim Union Budget (2024–25), which mentioned steps to introduce cervical cancer vaccination drives. Additionally, the programme aligns with the World Health Organization’s Cervical Cancer Elimination Initiative, which places emphasis on the vaccination of adolescent girls as part of a three-pronged strategy—the other components being screening and treatment to prevent cervical cancer—to reduce the global cervical cancer burden.
There are six globally licensed HPV vaccines, three of which are approved for use in India: Cervarix®, Gardasil®, and Gardasil-9®. Gardasil® is a tetravalent HPV vaccine that offers protection against four types of HPV—6, 11, 16, and 18. Types 16 and 18 are considered ‘high-risk’, as they contribute to the majority of HPV-related cancers. Gavi, the Vaccine Alliance, is supplying doses of Gardasil® to support India’s current HPV immunisation programme. Earlier this month, an extended follow-up study conducted in Sweden found that a single quadrivalent HPV vaccine dose significantly reduced the incidence of invasive cervical cancer and provided durable immunity for up to 18 years after vaccination. Similar observations have been reported in studies from England, Scotland, Denmark, and the Netherlands, demonstrating its ability to provide long-lasting immunity.
Expanding Access through Affordability and Innovation
India’s indigenous vaccine, Cervavac®, is manufactured by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT), BIRAC, and the Gates Foundation. Comprising HPV types 6, 11, 16, and 18, it was approved by the Drug Controller General of India (DCGI) in July 2022 and is available in India under a two-dose schedule. Cervavac® currently lacks WHO pre-qualification, limiting its inclusion in international procurement agencies such as Gavi. Evidence reviewed by the WHO Strategic Advisory Group of Experts on Immunization (SAGE) indicates that a single-dose regimen of the HPV vaccine has comparable efficacy to two- or three-dose schedules. India’s National Technical Advisory Group on Immunisation (NTAGI) has echoed similar conclusions and stipulated that immunisation in India can steer towards a single-dose regimen as further evidence emerges. Additional data on Cervavac® are needed, and studies assessing the efficacy of a single dose in adolescents aged 9–15 years are not yet complete.
Earlier this month, an extended follow-up study conducted in Sweden found that a single quadrivalent HPV vaccine dose significantly reduced the incidence of invasive cervical cancer and provided durable immunity for up to 18 years after vaccination.
Globally, vaccination efforts have become entangled with political considerations, contributing to the erosion of public trust in immunisation programmes. For instance, in the United States (US), routine childhood vaccine schedules have been revised, with the new schedule recommending 11 vaccines instead of the earlier 17. Alongside this, sporadic measles outbreaks have been reported across the country, reportedly fuelled by misinformation, undermining both vaccination programmes and scientific evidence. This politicisation is amplified through social media, extending beyond national borders and contributing to vaccine scepticism and hesitancy worldwide. Increased cases have been observed in six countries in the WHO’s European Region, with the United Kingdom (UK) losing its measles elimination status earlier this year.
Building Trust to Improve Vaccine Uptake
Under this setting, India’s continued push for HPV vaccination underscores the importance of sustained political commitment and public trust in vaccination programmes. This is not India’s first HPV vaccination drive. HPV vaccines were introduced in 2008, with state governments in Sikkim and Punjab launching programmes in 2016, alongside a pilot project in Delhi. However, these programmes recorded low uptake, despite the WHO South-East Asia Region (SEARO) accounting for the second-highest incidence of new cases and mortality from cervical cancer among WHO regions. This disproportionate burden is primarily attributed to the absence of a dedicated national immunisation strategy, limited organised screening and access to treatment, and broader social and economic factors. India accounts for over 65 percent of the regional burden, highlighting the need to strengthen efforts to combat a preventable form of cancer.
HPV vaccines were introduced in 2008, with state governments in Sikkim and Punjab launching programmes in 2016, alongside a pilot project in Delhi.
Several studies have evaluated the economic costs of HPV vaccination. In the Indian context, administering a single dose of the HPV vaccine to adolescent girls nationwide would yield substantial health and economic benefits. At a threshold of 30 percent of GDP per capita, a single dose of the HPV vaccine is considered cost-effective. A single-dose strategy is more affordable than a two-dose regimen and facilitates the implementation of vaccination protocols.
Improving HPV vaccine uptake in India requires a multi-pronged approach. Ensuring equitable access is being advanced through greater affordability, supported by both the current campaign and India’s affordable indigenous vaccine, Cervavac®. Dedicated efforts by healthcare providers to communicate accurate, evidence-based information will play a crucial role in raising awareness and countering misinformation. Improving health literacy can be achieved through training, counselling, and awareness campaigns targeting school-based and community outreach programmes. In Kenya, Maasai women, an ethnic group that typically aid mothers during childbirth, are entrusted with guiding parents and adolescent girls on HPV immunisation, thereby bridging the information gap. Efforts incorporating smartphone-based HPV campaigns and other digital health tools, such as social media and AI, can also contribute to improving health literacy.
HPV vaccine reminders, coupled with interactive educational content on the importance of immunisation, were deployed through text messaging in Uganda and promoted timely vaccine uptake. Concerns over vaccine safety and efficacy can be addressed through evidence dissemination and endorsement by trusted medical authorities or community healthcare workers to instil confidence. In addition, removing the stigma associated with HPV vaccination by framing it as a cancer-prevention tool will aid in normalising uptake and fostering societal acceptance. Further, positioning vaccination as an aspiration, or as a means to promote the well-being of a daughter, has been shown to improve vaccine uptake in Kenya. Collectively, these measures will enhance awareness, reduce misinformation, and instil confidence in HPV vaccines not only among adolescents receiving the vaccine but also among hesitant parents.
Concerns over vaccine safety and efficacy can be addressed through evidence dissemination and endorsement by trusted medical authorities or community healthcare workers to instil confidence. In addition, removing the stigma associated with HPV vaccination by framing it as a cancer-prevention tool will aid in normalising uptake and fostering societal acceptance.
The ongoing nationwide HPV vaccination programme will contribute to reducing the burden of cervical cancer and strengthening preventive healthcare in India. As the politicisation of vaccines and misinformation rises, public trust in immunisation is undermined. Expanding access through a single-dose strategy, alongside advancing indigenous manufacturing through Cervavac®, signifies a shift towards equitable and affordable long-term strategies. However, the success of these efforts depends on sustaining public trust by improving health literacy, instilling confidence among adolescents and parents, and addressing stigma and concerns over vaccine safety and efficacy. The disproportionate impact of cervical cancer on LMICs, alongside India’s rollout, offers an opportunity for India to act as a model in integrating science-driven policy measures, vaccine manufacturing, and affordable access to healthcare to improve women’s health outcomes.
Lakshmy Ramakrishnan is an Associate Fellow with the Centre for New Economic Diplomacy at the Observer Research Foundation.
The views expressed above belong to the author(s). ORF research and analyses now available on Telegram! Click here to access our curated content — blogs, longforms and interviews.